DECREASED POLYMORPHONUCLEAR LEUKOCYTE DEFORMABILITY IN NIDDM

被引:54
作者
PECSVARADY, Z
FISHER, TC
DARWIN, CH
FABOK, A
MAQUEDA, TS
SAAD, MF
MEISELMAN, HJ
机构
[1] UNIV SO CALIF, SCH MED, DEPT PHYSIOL & BIOPHYS, LOS ANGELES, CA 90033 USA
[2] UNIV SO CALIF, SCH MED, DIV DIABET HYPERTENS & NUTR, LOS ANGELES, CA 90033 USA
关键词
D O I
10.2337/diacare.17.1.57
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - To determine the theological properties of polymorphonuclear leukocytes (PMN) from non-insulin-dependent diabetes mellitus (NIDDM) patients. RESEARCH DESIGN AND METHODS - The deformability of PMN from 33 NIDDM subjects, 13 with impaired glucose tolerance (IGT), and 22 with normal glucose tolerance (NGT) was studied. A Cell Transit Analyzer that measures the transit time of PMN through 8-mu m pores was used. Studies were performed under three different conditions: 1) basal state; 2) after incubation with cytochalasin B (20 mu M) to dissociate f-actin from the cytoskeleton; and 3) following activation with N-formyl-methionyl-leucyl-phenylalanine (fMLP, 1 nM). RESULTS - I)MN from diabetic patients were more rigid (i.e., had longer transit time) than those from subjects with NGT or IGT under basal conditions and after cytochalasin B, but not after stimulation with fMLP. The deformability of PMN from subjects with IGT was similar to those of the NGT group. In the pooled data, basal transit time correlated with age; systolic and diastolic blood pressure; HbA(1c); and serum creatinine, cholesterol, and triglyceride concentrations (r = 0.29, 0.34, 0.37, 0.48, 0.25, 0.36, 0.29, respectively, P < 0.05 for each). Hypertensive diabetic patients had less deformable PMN than normotensive ones. No relation was found between PMN deformability and the duration of diabetes, type of treatment, or the presence of retinopathy. CONCLUSIONS - These data indicate increased rigidity of PMN in NIDDM that may contribute to development of microcirculatory disturbances and microangiopathy.
引用
收藏
页码:57 / 63
页数:7
相关论文
共 52 条
[1]  
ALLAIN CC, 1974, CLIN CHEM, V20, P470
[2]  
ANACHENKO VG, 1988, SOV MEDITISINA, V7, P32
[3]  
ANANCHENKO VG, 1986, SOVETSKAIA MEDITSINA, V10, P3
[4]  
[Anonymous], 1985, World Health Organ Tech Rep Ser, V727, P1
[5]  
Barnes A, 1987, CLIN HEMORHEOL, P275
[6]  
BARNES AJ, 1988, CLIN BLOOD RHEOLOGY, P163
[7]  
BAUERSACHS RM, 1989, CLIN HEMORHEOL, V9, P935
[8]   ROLE OF OXIDATIVE STRESS IN DEVELOPMENT OF COMPLICATIONS IN DIABETES [J].
BAYNES, JW .
DIABETES, 1991, 40 (04) :405-412
[9]  
BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
[10]  
BUCOLO G, 1973, CLIN CHEM, V19, P476